At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Leveraging our proprietary fit-for-purpose ROCK® (Redirected Optimized Cell Killing) platform, we develop innate cell engagers that are capable of reactivating innate immune cells to kill cancer cells and have the potential to overcome the limitations of traditional therapies. A number of clinical and preclinical programs are ongoing to study innate cell engagers in both hematological and solid tumors.
Diverse pipeline of innate cell engagers designed to activate innate immunity
Our differentiated preclinical and clinical pipeline comprises innate cell engagers designed to target both hematologic and solid tumors. Our CD16A-based innate cell engager AFM13 is the first to have reached the clinic and demonstrates evidence of a favorable safety profile and promising signs of therapeutic efficacy.
Innate Cell Engagers
Affimed fosters and continues to seek partnerships that are in line with the company’s overall corporate strategy to continue to move its clinical programs forward, enhance the development of Affimed’s internal pipeline and to allow for the technological advancement of our platform to realize the full potential of innate immune cells in oncology.
Learn more about our experienced Management Team with a proven track record in biotech, pharma, product development and finance.
Learn more about our Supervisory Board comprised of seasoned experts from the pharmaceutical and biotech industry.